Related Experiment Video

Updated: May 3, 2026

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

8.1K

Nanoparticles consisting of tocopheryl succinate are a novel drug-delivery system with multifaceted antitumor

Susumu Hama1, Kentaro Kogure

  • 1Department of Biophysical Chemistry, Kyoto Pharmaceutical University.

Biological & Pharmaceutical Bulletin
|February 5, 2014
PubMed

Insights

Tumor heterogeneity challenges cancer chemotherapy. This review introduces α-tocopheryl succinate (TS) nanoparticles as a novel drug-delivery system (DDS) carrier with inherent antitumor effects for combination therapy.

Area of Science:

  • Oncology
  • Nanotechnology
  • Drug Delivery Systems

Background:

  • Tumor heterogeneity significantly limits the effectiveness of conventional cancer chemotherapy.
  • Developing multifaceted treatment strategies is crucial for overcoming tumor heterogeneity and improving patient outcomes.
  • Combination therapy offers enhanced therapeutic effects over monotherapy by targeting diverse tumor aspects.

Purpose of the Study:

  • To introduce a novel drug-delivery system (DDS) carrier based on α-tocopheryl succinate (TS) nanoparticles.
  • To highlight the potential of TS nanoparticles as a multifaceted therapeutic agent for cancer combination therapy.
  • To explore the inherent antitumor activity of TS and its capability to form nanoparticles for drug delivery.

Main Methods:

  • Review of existing literature on tumor heterogeneity and combination chemotherapy.
  • Investigation of α-tocopheryl succinate (TS) as an antitumor agent.
  • Exploration of TS's self-assembly into nanoparticles for drug delivery applications.

Main Results:

  • α-Tocopheryl succinate (TS) exhibits unique antitumor properties.
  • TS can spontaneously form nanoparticles, serving as a potential drug-delivery system (DDS) carrier.
  • TS nanoparticles offer multifaceted antitumor effects, suitable for combination therapy.

Conclusions:

  • TS nanoparticles represent a novel DDS carrier with inherent antitumor activity.
  • This approach provides a multifaceted strategy to combat tumor heterogeneity in cancer treatment.
  • Further research into TS-based DDS for combination therapy holds significant promise for improving cancer chemotherapy efficacy.

More Related Videos

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

10.2K
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

14.2K

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
406
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
236